Table 1. Baseline characteristics.

|  |  |
| --- | --- |
| **Patient characteristics** | **All patients (n=460)** |
| Male, n (%) | 287 (62.4) |
| Age (years), median [IQR ] | 74 [67-79] |
| BMI (kg/m2), median [IQR]  Normal weight (BMI 22-28)  Underweight (BMI ≤22)  Overweight/obesity (BMI ≥28) | 26.9 [23.9-30.6]  180 (39.1)  52 (11.3)  147 (32.0) |
| eGFR (ml/min), median [IQR]  ≥ 50 ml/min  30-50 ml/min  15-30 ml/min  ≤ 15 ml/min | 68.0 [47-86]  329 (71.5)  83 (18.0)  32 (7.0)  11 (2.4) |
| Days of hospitalization, median [IQR] | 8 [5-13] |
| Type of anticoagulant therapy, n (%)  Double therapy (DAT)  Triple therapy (TAT) | 386 (83.9)  74 (16.1) |
| Type of oral anticoagulant, n (%)  VKA user  DOAC user | 215 (46.7)  245 (53.3) |
| Initiation therapy during current hospitalisation (newly initiated), n (%) | 360 (78.3) |
| Type of ward, n (%)  Cardiac (incl. cardiac surgery)  Surgical  Non-surgical | 291 (63.3)  69 (15.0)  100 (21.7) |
| Reason of hospitalization, n (%)  Cardiac  Bleeding  Thromboembolism  Other | 286 (62.2)  20 (4.3)  19 (4.1)  135 (29.3) |

N, number of patients; IQR, interquartile range; BMI, body mass index based on elderly > 70 years; eGFR, estimated glomerular filtration rate based on CKD-EPI formula; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant.